drugset / Trial / NCT00648999

Safety and Efficacy of Kaletra in ARV Therapy Experienced Patients

NCT00648999

Phase 4 Completed 207 enrolled AbbVie
Non-randomizedParallel-groupOpen-labelTreatment

Summary

To demonstrate that patients treated with Kaletra have an improvement in their quality of life compared to the quality of life they had with their previous NRTI therapy.

Timeline

Start
2003-11
Primary completion
2006-12
Completion
2006-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator Lopinavir Other / unclassified 400 mg
Comparator Ritonavir Other / unclassified 100 mg